arginine and dabrafenib

arginine has been researched along with dabrafenib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clements, A; Kefford, RF; Klein, O; Long, GV; Menzies, AM; O'Toole, S	1
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T	1

Other Studies

2 other study(ies) available for arginine and dabrafenib

Article	Year
BRAF inhibitor activity in V600R metastatic melanoma. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Compassionate Use Trials; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Valine; Young Adult	2013
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19 Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib	2013

Article

Year

BRAF inhibitor activity in V600R metastatic melanoma.

European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5

Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Compassionate Use Trials; Female; Humans; Imidazoles; Male; Melanoma; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Valine; Young Adult

2013

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-01, Volume: 31, Issue:19

Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib

2013